Navigation Links
Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc. (NASDAQ: INGN) and the Company's clinical collaborators today reported updated Phase 2 data demonstrating a significant correlation between abnormal p53, tumor responses and increased survival following ADVEXIN(R) therapy in patients with recurrent squamous cell carcinoma of the head and neck. The data (Abstract #6057) were presented today at the annual meeting of the American Society of Clinical Oncology in Chicago.

Tumor responses were assessed in 112 patients with recurrent head and neck cancer who received ADVEXIN. Overall, the percentages of patients with tumor responses defined by reductions in bi-dimensional tumor area on CT scan of 50 percent, 25 percent, 10 percent or stable disease for more than 2 treatment cycles were 6 percent, 7 percent, 12 percent and 22 percent, respectively. Median survival for these responder populations were 41, 17, 15 and 10 months, respectively. There was a statistically significant increase in median survival for each of the responder populations compared to the 6 month median survival of the non-responders (p less than 0.0016).

"The 41 month median duration of survival for the patients with a 50 percent or greater reduction in tumor size is very impressive and significantly greater than the six month median survival of non-responders that is typical for patients with recurrent tumors," said John Nemunaitis, M.D., Medical Director, Mary Crowley Medical Research Center. "Our findings are also consistent with a growing body of data that even smaller reductions in tumor size are clinically meaningful and are associated with increased survival."

The presentation also included data demonstrating that the predictive abnormal p53 biomarker was associated with a statistically significant increase in tumor responses to ADVEXIN therapy. A reduction in tumor size was observed in 40 percent of patients wi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
2. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
3. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/23/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... and sale of patented biopharmaceutical medicine, modernized traditional Chinese ... today announced the business and development progress at its ... Following the September 2014 JCM application (No. 51268) for ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to announce ... Vice President of Chemistry and Biochemistry. Scott joins the company ... Pharmaceuticals, and Amgen throughout the course of his nearly ... "Scott is a nationally recognized thought leader in ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... 8, 2011 Elsevier, world-leading provider of ... pleased to announce Dr. Steven Schachter, Editor-in-Chief of Elsevier,s ... the prestigious Ambassador for Epilepsy Award by the International ... Epilepsy (ILAE) at the 29 th International ...
... 2011 Marshall Edwards, Inc. (Nasdaq: MSHL ... of novel therapeutics targeting cancer metabolism, announced today the ... Company,s lead drug candidate ME-143 in patients with refractory ... with the Sarah Cannon Research Institute in Nashville, Tennessee, ...
Cached Medicine Technology:Editor-in-Chief of Elsevier's Epilepsy & Behavior presented with Ambassador for Epilepsy Award 2Editor-in-Chief of Elsevier's Epilepsy & Behavior presented with Ambassador for Epilepsy Award 3Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 2Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 3
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... in an effort to further promote visibility and adoption of ... long made AMA journals available via its subscription services, EBSCO ... Network. , Long known as both a subscription ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding ... its latest collection of wedding dresses , and launches a ... the wedding dress on your big day; the wedding gown ... bride wants to find the most suitable wedding dress. Now, ...
(Date:1/22/2015)... January 22, 2015 Lower-Auto-Insurance.com has released a new ... in a car for reducing the costs of an auto ... also be able to get lower prices for their vehicle insurance ... important role in determining policy costs. Because of this, drivers ...
(Date:1/22/2015)... State Forestry Institute of Mecklenburg-Vorpommern in Germany ... from GEOSYSTEMS, a dedicated Hexagon Geospatial and Intergraph partner ... Geospatial’s ERDAS APOLLO for cataloging, managing, and ... clouds and documents. This effort will enable the State ...
(Date:12/26/2014)... is said that nothing makes a lady feel more feminine ... supplier, shows its new selection of navy cocktail dresses ... UWDress.com’s navy cocktail gowns are the cornerstones of the site’s ... Simple dresses in bright neon colors can be dressed up ...
Breaking Medicine News(10 mins):Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2
... ... exams to uninsured diabetic patients. , ... Detroit, MI (Vocus) December 7, 2009 -- Mercy Primary Care Center of Detroit ... for the center’s diabetes management program serving uninsured residents in the city. In an effort ...
... , CAMP HILL, Pa., Dec. 7 Highmark ... organizations in which Highmark employees volunteer. Through Highmark,s Employee ... benefit the agencies they hold close to their hearts ... program reinforces the company,s appreciation for employees who volunteer ...
... , Advisory articles ... , HARRISBURG, Pa., Dec. 7 All Pennsylvania registered nurses can ... Safety Advisory articles that are posted on the Pennsylvania State ... law requires registered nurses to have 30 hours of continuing education ...
... successfully performed kidney transplants after removing small cancerous and ... results in the December issue of the urology journal ... at the University of Maryland School of Medicine in ... end-stage renal disease as well as increasing the supply ...
... , ... experts at Kroll Fraud Solutions will host a webinar that outlines important steps healthcare ... for Economic and Clinical Health Act (HITECH) , ... Nashville, TN (PRWEB) December 7, 2009 -- Data security ...
... ... consultancy, to offer top-of-the-line implementation services to Talyst’s clients in the acute care ... ... Clinical Meeting of the American Society of Health-System Pharmacists in Las Vegas, Talyst ...
Cached Medicine News:Health News:Mercy Primary Care Center Receives $15,000 in Matching Grants for Diabetes Management Program, 2Health News:Mercy Primary Care Center Receives $15,000 in Matching Grants for Diabetes Management Program, 3Health News:Highmark Inc. Employees Earn $7,000 for Nonprofit Organizations 2Health News:PA Registered Nurses Can Earn Continuing Education Hours Through Pennsylvania Patient Safety Advisories 2Health News:Controversial kidney transplant technique could provide lifeline for very ill patients 2Health News:Kroll Fraud Solutions to Host Webinar for Healthcare Organizations on Achieving HITECH Compliance 2Health News:Kroll Fraud Solutions to Host Webinar for Healthcare Organizations on Achieving HITECH Compliance 3Health News:Talyst and RXinnovate Partner on Pharmacy Automation Implementation 2
... The Deluxe specimen bath mounts inside the ... bath allows for the separation of buffer and ... The bath can be sterilized and has round ... mounting specimens. The disks and bath surface ...
... A simple device designed to mount ... This product facilitates the mounting of all ... It is especially useful for mounting tissue ... as those produced with a Vibratome, freezing ...
Punch set for Advanced Tissue Arrayer, 0.6 mm...
Inquire...
Medicine Products: